Nanjing Hicin Pharmaceutical Co Ltd

Nanjing Hicin Pharmaceutical Co Ltd has a debt-to-equity ratio of 0.27, indicating a relatively conservative capital structure with limited leverage. The company's liquidity position is characterized as medium risk, with a current ratio of 1.04, suggesting that it has just enough current assets to cover its current liabilities. Free cash flow for the period was 22,213,070 CNY, while operating cash flow was 78,089,130 CNY, indicating that the company generates positive cash from operations but has limited excess after capital expenditures.

Profitability metrics show a return on equity (ROE) of 3.99% and a return on assets (ROA) of 2.75%. These figures are below the typical thresholds for high-performing pharmaceutical firms, suggesting that the company is not generating strong returns relative to its equity and asset base. The net income of 42,058,390 CNY and operating income of 45,693,880 CNY reflect modest profitability, with a gross profit margin of 81.5% (546,857,380 CNY / 671,048,950 CNY).

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks. The company's revenue of 671,048,950 CNY is in line with the analyst estimate of 704,087,740 CNY, indicating that the company is performing in line with expectations.

Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. Capital expenditures were negative at -62,639,930 CNY, suggesting that the company is not investing heavily in new projects or infrastructure. This could indicate a focus on cost control or a lack of expansion opportunities.

The company faces moderate liquidity risk, as its net cash position is negative after subtracting total debt. This suggests that the company may need to rely on external financing or operating cash flow to meet its obligations. The risk of dilution is assessed as low, with no significant dilution events expected in the near term. The company has not issued additional shares recently, and there is no indication of a pending equity offering.

Recent financial filings and disclosures show that the company has maintained a stable financial position, with no major events or earnings surprises reported. The company's financial statements show consistent performance, with no material changes in its operating or financial structure. The company has not issued any new products or entered into significant partnerships that would impact its revenue or market position.